Home » Authors » Jim Shrine

Articles by Jim Shrine

Marcadia Raises $15M In First Round For Metabolic Programs

May 16, 2007

ProCertus Completes Series A Financing For Cancer Programs

May 11, 2007

ProCertus Completes Series A Financing For Cancer Programs

May 11, 2007

Avid Raises $26M In Series C For Molecular imaging Agents

May 10, 2007

Avid Raises $26M In Series C For Molecular imaging Agents

May 10, 2007

Progen Raising $61M To Fund Phase III Cancer Trials Of PI-88

May 4, 2007

Progen Raising $61M To Fund Phase III Cancer Trials Of PI-88

May 4, 2007

Array Raises $91M Publicly For Cancer, Inflammation Programs

May 3, 2007

Array BioPharma Inc. raised $91 million in a public offering of stock, money that will be used to fund development of its broad, early stage pipeline of small-molecule drug candidates for cancer and inflammatory diseases. (BioWorld Today)

Array Raises $91M Publicly For Cancer, Inflammation Programs

May 3, 2007

Array BioPharma Inc. raised $91 million in a public offering of stock, money that will be used to fund development of its broad, early stage pipeline of small-molecule drug candidates for cancer and inflammatory diseases. (BioWorld Today)

Italian Firm Eurand Files For IPO On Nasdaq Of Up To $153M

May 2, 2007

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 12, 2024.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for December 12, 2024.
Second insulin receptor offers new therapeutic avenues
BioWorld Science
Investigators at the Helmholtz Institute have shown that inceptor, an inhibitor of the insulin signaling pathway, acted by binding insulin and targeting it for...
KITE-753, a rapid manufactured CAR T therapy with superior antitumor efficacy and enhanced expansion in vivo
BioWorld Science
In a presentation at the recent American Society of Hematology meeting in San Diego, Kite Pharma Inc. reported preclinical data for KITE-753, an autologous rapid...
Keros stock wilts as it halts two dosing arms in hypertension study
BioWorld
After Keros Therapeutics Inc.’s voluntary halt of dosing in two arms of its phase II study in pulmonary arterial hypertension, the company’s stock crumpled after...

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.